KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 103 filers reported holding KEROS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $164,000 | -20.4% | 5,123 | -0.2% | 0.00% | – |
| Q2 2023 | $206,000 | +102.0% | 5,135 | +114.7% | 0.00% | – |
| Q1 2023 | $102,000 | -28.7% | 2,392 | -19.3% | 0.00% | – |
| Q4 2022 | $143,000 | +694.4% | 2,965 | +519.0% | 0.00% | – |
| Q3 2022 | $18,000 | +80.0% | 479 | +34.6% | 0.00% | – |
| Q2 2022 | $10,000 | -85.1% | 356 | -71.2% | 0.00% | – |
| Q1 2022 | $67,000 | -68.8% | 1,235 | -66.4% | 0.00% | – |
| Q4 2021 | $215,000 | +277.2% | 3,676 | +156.5% | 0.00% | – |
| Q3 2021 | $57,000 | +16.3% | 1,433 | +22.6% | 0.00% | – |
| Q2 2021 | $49,000 | -38.0% | 1,169 | -8.9% | 0.00% | – |
| Q1 2021 | $79,000 | +154.8% | 1,283 | +187.7% | 0.00% | – |
| Q4 2020 | $31,000 | +675.0% | 446 | +341.6% | 0.00% | – |
| Q3 2020 | $4,000 | 0.0% | 101 | +1.0% | 0.00% | – |
| Q2 2020 | $4,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |